期刊文献+

纽甜:安全性和功能作用综述 被引量:12

Summary of the Safety and Function of Neotame
下载PDF
导出
摘要 纽甜(N-[N-(3,3-二甲基丁基)-L-a-天冬氨酸]-L-苯丙氨酸1-甲酯)是一种新型的非营养类增甜剂和强味剂,它的甜度大约是蔗糖的7000到13000倍。纽甜不提供能量,它具有类似蔗糖的纯正甜味,没有任何杂味。纽甜既可以单独地也可以与其它非营养类和营养类增甜剂一起用于各种食物和饮料中。纽甜吸收很快但只是部分地被吸收。在体内,它的主要代谢途径是通过去酯化形成脱酯化的纽甜和微量的甲醇。它们被很快地从血浆中清除,最后经过粪便和尿液完全地排出体外。由于纽甜分子中含有3,3-二甲基丁基组,能够几乎完全地阻断该肽酶的功用,从而减少了苯丙氨酸的形成。因此,纽甜可用于苯丙酮酸尿症的患者而不需要特殊的商标注明。用剂量数千倍于预测人类消耗剂量的纽甜对包括大鼠、小鼠、狗和兔在内的试验动物所进行的一系列综合性安全试验证实了纽甜没有靶器官毒性,致畸、致癌作用,对生殖系统也没有影响。此外,用细菌和哺乳动物做试验没有发现纽甜有致突变作用,也没有发现对各种器官组织的药理作用。用健康人群做的耐受试验证实纽甜不影响人体的临床或生化指标并且与安慰剂相比没有副作用。进一步的试验证实纽甜对二型糖尿病患者的血糖或胰岛素浓度没有影响。多项试验的结果确认纽甜可以安全的用于包括儿童。
出处 《中国食物与营养》 2004年第7期32-46,共15页 Food and Nutrition in China
  • 相关文献

参考文献88

  • 1Blackburn GL, Kanders BS, Lavin PT, Keller S.D, Whatley J: The effect of aspartame as part of a multidisciplinary weight-control program on short- and long-term control of body weight. Am J Clin Nutr 65:409-418, 1997. 被引量:1
  • 2DuBois GE, Waiters DE, Schiffman SS, Warwick ZS, Booth B J, Pecore SD, Gibes K, Carr BT, Brands LM.: Concentration-response relationships of sweeteners In: Walters DE, Orthoefer FT, DuBois GE (eds).""Sweeteners Discovery, Molecular Design, and Chemorecept 被引量:1
  • 3Butchko HH, Kotsonis FN: Acceptable daily intake and estimation of consumption. In: Tschanz C,Butchko HH, Stargel WW, Kotsonis FN (eds): ""The Clinical Evaluation of a Food Additive: Assessment of Aspartame."" Boca Raton, FL: CRC Press, pp 43-53,996. 被引量:1
  • 4Butchko HH, Stargel WW, Comer CP, Mayhew DA, Benninger C, Blackburn GL, de Sonneville LMJ,Geha RS, Hertelendy Z, Koestner A, Leon AS, Liepa GU, McMartin KE, Mendenhall CL, Munro IC, Novotny E J, Renwick AG, Schiffman SS, Schomer DL, Shaywitz BA, Spiers PA 被引量:1
  • 5Hawkins D, Kirkpatrick D, Aikens P, Saxton J: PCR 1028. NC-00723: Pharmacokinetics of Single Doses in the Rat After Oral and Intravenous Administration. Huntingdon Life Sciences Ltd., research report submitted to the Food and Drug Administration, FAP 8A45 被引量:1
  • 6Kirkpatrick D, Aikens P, Nicholson J, Saxton J, Harris K.. PCR 1029. 14C-NC-00723 Metabolism and Pharmacokinetics in the Dog. Huntingdon Life Sciences Ltd., research report submitted to the Food and Drug Administration, FAP 8A4580. 1997c 被引量:1
  • 7Hawkins D, Kirkpatrick D, Aikens P, Saxton J: PCR 0959. 14C-NC-00723: Tissue Distribution in the Rat. Huntingdon Life Sciences Ltd., research report submitted to the Food and Drug Administration, FAP 8A4580. 1995a. 被引量:1
  • 8Hawkins D, Kirkpatrick D, Aikens P, Beeby T: PCR 0958. 14C-NC-00723: Determination of the Distribution in Rats by Whole-Body Autoradiography.Huntingdon Life Sciences Ltd., research report submitted to the Food and Drug Administration, FAP 8A4580.1995b. 被引量:1
  • 9Hawkins D, Aikens P, Beeby T: PCR 1031.14C-NC-00723: Determination of the Distribution in Pregnant and Non-Pregnant Rats by Whole-Body Autoradiography. Huntingdon Life Sciences Ltd., research report submitted to the Food and Drug Administration, FAP 8A458 被引量:1
  • 10Turk M, David E, Bartekian V: PCR 1044.Measurement of Concentrations of NC-00723 and NC00751 in Plasma Samples from a 104 Week Carcinogenicity Study in Mice. Phoenix International Life Sciences Inc., addendum to research report PCR 1014 submitted to the F 被引量:1

同被引文献77

引证文献12

二级引证文献63

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部